Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ari Feinstein
Federal Circuit to Consider Scope of Patent Infringement Liability for Government Contractors in Arbutus v. Moderna
Skip to content IP + Technology Law Home » News & Insights » Blogs » Biotechnology | Share Related Links Litigation Patent Litigation Biotech
In Journal of IP & Technology Law, Ari Feinstein and Charlene Azema Offer Roadmap to Litigating Lack-of-Bona Fide Intent Claims at the TTAB
In a recent article published in the Journal of Intellectual Property & Technology Law, Knobbe Martens partners Ari Feinstein and Charlene Azema explore strategies for asserting and defending against lack-of-bona fide intent claims at the Trademark Trial and Appeal Board (TTAB).
Courts Must Address Pre-Suit Invalidity Red Flags When Denying Sanctions and Fees
EPIC TECH, LLC V. PEN-TECH ASSOCIATES, INC. Before Moore, Cunningham, and Subramanian (District Judge for U.S. District Court for the Southern District of New York, sitting by designation). Appeal from the U.S. District Court for the Northern District of Georgia. Summary: A district court must adequately explain its reasoning for denying motions for sanctions and attorneys’ fees to permit meaningful appellate review. Epic Tech, LLC (“Epic Tech”) sued Pen-Tech Associates, Inc.
Is That a Rule 54(b) “Final Judgment”? A Stark Contrast Between Disposing All and Less Than All Asserted Claims of a Patent
PARKERVISION, INC. v. QUALCOMM INCORPORATED Before Prost, Chen, and Stark. Appeal from the United States District Court for the Middle District of Florida. Summary: Since infringement of a patent is a single cause of action, a judgment that does not address all of the still-asserted claims of a patent is not a “final judgment” for Rule 54(b) purposes. ParkerVision, Inc. sued Qualcomm for infringement of the ’940 patent.
Is That a Rule 54(b) “Final Judgment”? A Stark Contrast Between Disposing All and Less Than All Asserted Claims of a Patent
Skip to content IP + Technology Law Home » News & Insights » Blogs » Litigation | Share Related Links Litigation Patent Litigation Communications Technology
Life Science Update | August 2026
No “Duty to Innovate” – California’s Highest Court Finds Gilead Sciences Not Negligent for Delaying Release of Allegedly Safer HIV Drug Ari Feinstein & Rhett D. Ramsey California court holds that drug manufacturers do not have a duty to commercialize a safer drug to replace a nondefective one. FDA Approves First mRNA-Based Flu Vaccine, Highlighting Growing Patent Value in mRNA Platforms Jason J. Jardine & Alistair J.
The Problem with Defining the “Problem”: Federal Circuit Affirms Flexible Analogous-Art Analysis
Skip to content IP + Technology Law Home » News & Insights » Blogs » PTAB | Share Related Links Litigation Patent Litigation Patent Trial & Appeal Board (PTAB) Trials (Post Grant) Electrical, Semiconductor & Computer Technology Software & IT
Five Knobbe Martens Partners Recognized in Benchmark Litigation “40 & Under” Guide
IRVINE, Calif., August 27, 2026 – Knobbe Martens is proud to share that five of the firm’s partners were named in the 2026 edition of Benchmark Litigation’s “40 & Under” guide.
No “Duty to Innovate” – California’s Highest Court Finds Gilead Sciences Not Negligent for Delaying Release of Allegedly Safer HIV Drug
Skip to content IP + Technology Law Home » News & Insights » Blogs » Biotechnology | Share Related Links Litigation Biotech Pharmaceuticals
How US courts are addressing fair use questions in AI training and copyright disputes
As generative AI continues to scale, one legal question sits at the centre of industry debate: what restrictions does copyright law place on using data to train AI models? The answer is emerging from the US courts and is generally favourable to AI developers but with crucial caveats. To better explain how companies can navigate these as they train their AI models, it is vital to break down these decisions further.
AI Training and Fair Use
Key Takeaways: While the legal landscape is continuing to take shape, a number of recent court decisions indicate that unlicensed use of copyrighted data to train AI models generally constitutes fair use. Each fair use inquiry depends on the facts at play, however, including, among other things, how the AI model’s output compares to the copyrighted data that was input into the model.
PTAB Update | April 2026
USPTO Introduces Pre-Order Papers for Patent Owners in Ex Parte Reexaminations Jarom D. Kesler & Joshua M. Martineau With the decline of inter partes review (IPR) proceedings and the significant increase in ex parte reexamination (EPR) proceedings, the U.S. Patent and Trademark Office (USPTO) is allowing EPR patent owners to submit a new “pre-order” paper prior to the USPTO’s institution decision.
Standing Still? Only if Injury-In-Fact Is Tied to the Claims at Issue
IRONSOURCE LTD. v. DIGITAL TURBINE, INC. Before Moore, Lourie, and Reyna. Appeal from the Patent Trial and Appeal Board. Summary: An appellant seeking to establish Article III standing based on an injury-in-fact flowing from the appellee’s challenged patent must link its own product to the claims at issue. ironSource Ltd. (“ironSource”) petitioned the Patent Trial and Appeal Board (the “Board”) for post-grant review (PGR) of certain claims of a patent owned by Digital Turbine, Inc. (“DT”).
Litigation Update | March 2026
The Credibility of Experts Is in the Province of the Jury Ari Feinstein & Kathryn M. McCarthy Neither the fact that a damages expert’s testimony could have been presented more clearly, nor the fact that the methodology could be subject to reasonable disagreement, is a basis to exclude the expert’s testimony. How Ignoring Disclosed Structure Can Derail a Means-Plus-Function Case Douglas B. Wentzel & Stella B.
The Credibility of Experts Is in the Province of the Jury
WILLIS ELECTRIC CO., LTD. v. POLYGROUP LTD. (MACAO COMMERCIAL OFFSHORE) Before Moore, Stark, and Oetken (sitting by designation). Appeal from the United States District Court for the District of Minnesota. Summary: Neither the fact that a damages expert’s testimony could have been presented more clearly, nor the fact that the methodology could be subject to reasonable disagreement, is a basis to exclude the expert’s testimony. Willis Electric Co., Ltd. (Willis) sued Polygroup Ltd.
Presented by Netflix—Grammar Police: An Exercise in Claim Construction | JD Supra
NETFLIX, INC. V. DIVX, LLC Before Moore, Dyk, and Taranto. Appeal from the Patent Trial and Appeal Board. Summary: Common principles of English grammar may be used to identify the presumptively correct interpretation of a disputed claim term. Netflix, Inc. petitioned the Patent Trial and Appeal Board (Board) to institute inter partes review (IPR) of all claims of U.S. Patent No. 10,225,588 (“the ’588 patent”), a patent owned by DivX, LLC.
Challenged Director-To-PTAB Instructions Did Not Require Notice-And-Comment Rulemaking | JD Supra
APPLE INC. v. SQUIRES Before Lourie, Taranto, and Chen. Appeal from the United States District Court for the Northern District of California. Summary: Challenged instructions that the PTO’s Director gave to the PTAB regarding discretionary denial of inter partes review petitions are general statements of policy and thus not subject to the notice-and-comment rulemaking requirements of the Administrative Procedure Act. Apple Inc.
Life Science Update | December 2025 | JD Supra
Purdue Pharma’s $7.4 Billion Chapter 11 Plan Formally Approved Eric Furman, Ph.D. & Rhett D. Ramsey A federal bankruptcy court on November 18 formally approved Purdue’s $7.4 billion Chapter 11 plan to settle thousands of opioid-related lawsuits. The plan requires (1) a $6.5 billion contribution from the Sackler family members who own Purdue and (2) a $900 million contribution from Purdue itself.
Proposed Legislation to Codify “Skinny Label” Safe Harbor | JD Supra
On December 5, 2025, the Skinny Labels, Big Savings Act (H.R. 6485) was introduced in the House of Representatives.
Life Science Update | October 2025 | JD Supra
USPTO, JPO, and EPO Meet to Discuss Global IP Challenges Joseph Mallon, Ph.D. & Ashley C. Morales Beginning on October 20, 2025, recently confirmed United States Patent and Trademark Office (USPTO) Director John A. Squires met with European Patent Office (EPO) Vice-President Steve Rowan and Japanese Patent Office (JPO) Commissioner Yasuyuki Kasai for a two-day meeting as part of the AI and the Fight Against Antimicrobial Resistance Robert J. Hilton, Ph.D. & Bailey R.
Little League® Remembers Longtime East Region Volunteer, Catherine M. Madden
After a long-fought battle with cancer, Little League® International mourns the passing of Catherine M. Madden, a longtime East Region volunteer. As an experienced Registered Nurse, Madden worked for New Britain General Hospital, Bristol VNA, and the Torrington School District throughout her career. Passionate about baseball and giving back to her community, when Madden wasn’t working as an RN, she could be found at the A.
"Improper” Listing of Patents in the FDA’s Orange Book
As we previously discussed, on November 7, 2023, the Federal Trade Commission (“FTC”) sent warning letters to certain drug manufacturers regarding their purportedly improper listings of device patents in the Food and Drug Administration’s (“FDA”) Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book” or “OB”).
Antitrust Lawsuit Brought Against Drug Manufacturer Based on Its Allegedly Improper Listing of Device Patents in the FDA’s Orange Book | JD Supra
As we recently discussed, the Federal Trade Commission (“FTC”) sent warning letters to certain drug manufacturers regarding their purportedly improper listing of device patents in the Food and Drug Administration’s (“FDA”) Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book”).
Antitrust Lawsuit Brought Against Drug Manufacturer Based on Its Allegedly Improper Listing of Device Patents in the FDA’s Orange Book
As we recently discussed, the Federal Trade Commission (“FTC”) sent warning letters to certain drug manufacturers regarding their purportedly improper listing of device patents in the Food and Drug Administration’s (“FDA”) Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book”).
Shire v. Blackburn: Drawing the Line Between FDA Drug Labeling Regulations and State Law on Product Liability | JD Supra
On June 2, 2023, drug manufacturer Shire US Inc. and related entity Shire LLC (collectively, “Shire”) asked the Supreme Court to review an Eleventh Circuit ruling involving the interplay between state tort law and FDA regulations regarding drug labels.
Shire v. Blackburn: Drawing the Line Between FDA Drug Labeling Regulations and State Law on Product Liability
On June 2, 2023, drug manufacturer Shire US Inc. and related entity Shire LLC (collectively, “Shire”) asked the Supreme Court to review an Eleventh Circuit ruling involving the interplay between state tort law and FDA regulations regarding drug labels.
Teva v. GSK: The “Skinny” Label Case Pending Before the Supreme Court | JD Supra
On March 29, 2023, the Solicitor General of the United States asked the Supreme Court to review a Federal Circuit judgment in a Hatch-Waxman case between Teva and GSK. In its decision below, the Federal Circuit held that Teva could be held liable for inducement based on language in its “skinny label” and reinstated a $235 million jury award to GSK that the district court had set aside.
Teva v. GSK: The “Skinny” Label Case Pending Before the Supreme Court
On March 29, 2023, the Solicitor General of the United States asked the Supreme Court to review a Federal Circuit judgment in a Hatch-Waxman case between Teva and GSK. In its decision below, the Federal Circuit held that Teva could be held liable for inducement based on language in its “skinny label” and reinstated a $235 million jury award to GSK that the district court had set aside.
Judge Allows Facebook to Settle Facial Scanning Suit for $650 Million | JD Supra
On February 26, 2021, Judge James Donato of the U.S. District Court for the Northern District of California granted final approval of a proposed $650 million settlement in a biometric privacy class action lawsuit brought against Facebook. In re Facebook Biometric Information Privacy Litigation, Case No. 3:15-cv-03747-JD, Dkt. No. 537 (N.D. Cal. Feb. 26, 2021).
No Kitchen Confusion: When Comparing Marks, the Trademark Board Can Give Less Weight to Shared Terms if the Terms Are Suggestive or Descriptive | JD Supra
QUIKTRIP WEST, INC. V. WEIGEL STORES, INC. Before Lourie, O’Malley, and Reyna. Appeal from the Trademark Trial and Appeal Board. Summary: When comparing marks under the Dupont factors, the Board may give less weight to shared terms that are highly suggestive if not descriptive. Further, a party’s willingness to alter its mark multiple times to prevent customer confusion demonstrates a lack of bad faith. In 2014, Weigel Stores, Inc.
No Kitchen Confusion: When Comparing Marks, The Trademark Board Can Give Less Weight To Shared Terms If The Terms Are Suggestive Or Descriptive
United States: No Kitchen Confusion: When Comparing Marks, The Trademark Board Can Give Less Weight To Shared Terms If The Terms Are Suggestive Or Descriptive 11 January 2021 by Ari Feinstein and Daniel P. Hughes Knobbe Martens To print this article, all you need is to be registered or login on Mondaq.com. QUIKTRIP WEST, INC. V. WEIGEL STORES, INC. Before Lourie, O'Malley, and Reyna. Appeal from the Trademark Trial and Appeal Board.
Data Breach: No Injury-in-Fact, Case Dismissed | JD Supra
It well known that there are, unfortunately, many data breaches that frequently put private citizens’ data privacy in jeopardy. States have passed a variety of statutes aimed at addressing this problem in an attempt to provide data breach victims with some form of redress. Nonetheless, even where there has been a data breach, a plaintiff must meet certain requirements in order to have standing to bring a lawsuit in an Article III court.
Criminal Enforcement Against Data Breaches Under the Computer Fraud and Abuse Act | JD Supra
On April 20, 2020, the U.S. Supreme Court granted writ of certiorari in Van Buren v. United States to consider whether a person who is authorized to access information on a computer for certain purposes violates Section 1030(a)(2) of the Computer Fraud and Abuse Act (“CFAA”) if he accesses the same information for an improper purpose. Oral argument before the Supreme Court will be held on November 30, 2020.
Imaginary Slice of Accused Product Failed to Satisfy Structural Claim Limitation | JD Supra
NEVILLE v. FOUNDATION CONSTRUCTORS, INC. Before Lourie, O’Malley, and Chen. Appeal from the United States District Court for the Central District of California. Summary: The Federal Circuit affirmed a construction of “end plate” that required a flat external surface, and therefore precluded an infringement theory in which the “end plate” was an imaginary slice inside the accused product. Plaintiffs Steve Neville, Substructure Support, Inc., and TDP Support, Inc.
Non-Infringement Need Not Be “Actually Litigated” to Shield Accused Products From Infringement Liability in Subsequent Actions | JD Supra
In Re Personal Web Technologies LLC Before Wallach, Bryson, and Taranto. Appeal from the United States District Court for the Northern District of California. Summary: The Kessler doctrine is not limited to cases involving a finding of non-infringement; it applies to cases that are dismissed with prejudice. PersonalWeb Technologies LLC (“PersonalWeb”) sued dozens of Amazon’s customers alleging infringement of several related patents.
Do Not Bank on a Bank Not Being a “Person” Under the AIA | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Non-Prior Art Evidence May Be Used to Prove Inherency | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Terms of Degree with Objective Boundaries Are Not Indefinite | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Metadata of conception documents could help independently corroborate inventor testimony of prior conception | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Federal Circuit: trademark decisions rendered by International Trade Commission do not have preclusive effect
04 Jun 2019 @WTRmagazine BASCAP provides blueprint for Vietnam to fight fakes: "There is a lot more to do".
Federal Circuit: trademark decisions rendered by International Trade Commission do not have preclusive effect
20 May 2019 @WTRmagazine RT @EUROBSIT: INTA (@INTABrussels) study reveals Generation Z’s attitude to counterfeits: 57% believe their money is better off benefiting… Read more 20 May 2019 @WTRmagazine RT @WTRmagazine: At #INTA2019?
Trademark Decisions Rendered by the International Trade Commission Do Not Have Preclusive Effect | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Yeda Research And Development Co., Ltd. v. Mylan Pharmaceuticals Inc. & Teva Pharmaceuticals USA, Inc. v. Sandoz Inc. | JD Supra
JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations. This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services").
Supreme Court to Review Post-AIA On-Sale Bar
Call 855-808-4530 or email GroupSales@alm.com to receive your discount on a new subscription. The U.S. Supreme Court agreed to consider a question raised by Helsinn Healthcare: whether, under the Leahy-Smith America Invents Act (AIA) an inventor’s sale of an invention to a third party that is obligated to keep the invention confidential qualifies as prior art for purposes of determining the patentability of the invention.
Endo Pharmaceuticals Solutions v. Custopharm Inc. | JD Supra
JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations. This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services").
Dell Inc. v. Acceleron, LLC | JD Supra
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Already signed up? Log in here By using the service, you signify your acceptance of JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources.
Jury’s Award for Patent Infringement Increased to 3 Million for Infringing Window Blinds Components | JD Supra
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Already signed up? Log in here By using the service, you signify your acceptance of JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ari
Contact Ari, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack